Skip to main content
SkinCited

Lactobacillus rhamnosus pour Eczema (Atopic Dermatitis)

B Preuves Au moins un essai randomisé le soutient, avec des résultats globalement concordants.

Meta-analyses found L. rhamnosus GG reduced the risk of atopic dermatitis by approximately 50% in high-risk infants and improved SCORAD scores in children with established eczema.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'skincited.com'; const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u0026condition\u003Deczema\u002Datopic\u002Ddermatitis'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

En conclusion

Meta-analyses found L. rhamnosus GG reduced the risk of atopic dermatitis by approximately 50% in high-risk infants and improved SCORAD scores in children with established eczema.

Key Study Findings

Review
Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG.
Dose: None vs: None Outcome: Diarrhea, colic, allergy, atopic dermatitis Effet: None None

Population: Pediatric patients

Randomized Controlled Trial
[Effectiveness and safety of probiotics in children on the basis of clinical trials].
Dose: None vs: None Outcome: diarrhea Effet: None None

Population: None

Key Statistics

20

Études

3500

Participants

Positive

B

Note

Referenced Papers

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Posologies couramment utilisées

general:
1-10 billion CFU/day
atopicdermatitis:
10 billion CFU/day L. rhamnosus GG

Limite supérieure : Not established; generally well-tolerated at doses up to 100 billion CFU/day

Posologies étudiées dans la recherche

Posologie Durée Effet N
None -- Positive --
None -- Positive --

Moment optimal de prise : Before or with meals; some studies suggest empty stomach

Safety & Side Effects

Effets indésirables signalés

  • Mild gas or bloating (temporary, during initial use)
  • Rare infections in severely immunocompromised individuals

Interactions connues

  • Immunosuppressants (theoretical concern — live bacteria)
  • Antibiotics (may reduce probiotic viability — separate by 2+ hours)

Apport maximal tolérable : Not established; generally well-tolerated at doses up to 100 billion CFU/day

Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.

Frequently Asked Questions

Does Lactobacillus rhamnosus help with Eczema (Atopic Dermatitis)?
Based on 20 studies with 3,500 participants, there is moderate evidence from clinical studies that Lactobacillus rhamnosus may support Eczema (Atopic Dermatitis) management. Our evidence grade is B (Good Evidence).
How much Lactobacillus rhamnosus should I take for Eczema (Atopic Dermatitis)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus rhamnosus?
Reported side effects may include Mild gas or bloating (temporary, during initial use), Rare infections in severely immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus rhamnosus and Eczema (Atopic Dermatitis)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 20 peer-reviewed studies with 3,500 total participants. The overall direction of effect is positive.

Lactobacillus rhamnosus pour d'autres pathologies

References

  1. [1] Christian Boggio Marzet et al.. Arch Argent Pediatr. 2022. Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG. doi:10.5546/aap.2022.eng.e1 PubMed
  2. [2] Ewa Kamińska. Med Wieku Rozwoj. 2012. [Effectiveness and safety of probiotics in children on the basis of clinical trials]. PubMed

Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.